GlassScriptPhysician profile
Ahmad Mafi
NPI 1003312455
$2,488.81
in general payments reported to CMS, 2019-2025
36 companies · $844 in 2025
The $844 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $751 · 2023: $223 · 2024: $515 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $281.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $168.23 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $148.03 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.40 | 2021-2023 | Stiolto Respimat |
| Pfizer INC. | $117.32 | 2021-2025 | |
| Abbott Laboratories | $116.28 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $101.76 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $86.59 | 2022-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $79.31 | 2022-2025 | Entyvio |
| Otsuka America Pharmaceutical, INC. | $73.67 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $66.42 | 2024-2025 | |
| Madrigal Pharmaceuticals | $63.64 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $53.85 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Corcept Therapeutics | $49.74 | 2025 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.98 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $35.69 | 2021-2023 | Repatha |
| Eisai INC. | $34.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.21 | 2024 | |
| Daiichi Sankyo INC. | $28.92 | 2024 | Injectafer |
| Genzyme Corporation | $26.18 | 2024 | |
| Jazz Pharmaceuticals INC. | $24.27 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.14 | 2024 | Xtampza |
| Abbvie INC. | $19.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.94 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.37 | 2024 | Givlaari |
| Ultragenyx Pharmaceutical INC. | $18.02 | 2022 | |
| Seqirus USA INC | $17.15 | 2025 | Fluad, Flucelvax |
| Insulet Corporation | $16.33 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $16.17 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $15.16 | 2025 | Symbravo |
| Biogen, INC. | $14.22 | 2025 | Zurzuvae |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2021 | |
| Shield Therapeutics INC | $13.76 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Mafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.